TX-STATLAB
28.8.2024 13:06:34 CEST | Business Wire | Press release
StatLab Medical Products (“StatLab”), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has reached an agreement to acquire Diapath S.p.A. (“Diapath”), a prominent Italian manufacturer of histology and cytology products and equipment. The integration of Diapath, with its highly innovative equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, Middle East and Africa, and Latin America, positions StatLab to expand its market access, unlocking significant potential for growth and enhancing its global leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828096902/en/
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. (Photo: Business Wire)
The transaction is expected to close during the third quarter of 2024, subject to regulatory approvals. Upon closing, Diapath founder Vladimiro Bergamini will transition to a senior advisor role at StatLab, and Chief Operating Officer Alberto Battistel will join StatLab’s executive leadership team and help steer the Diapath business unit as its Managing Director.
“This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” said Sung-Dae Hong, CEO of StatLab. “Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the U.S. The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level. I’m excited to welcome Alberto and the talented Diapath team to StatLab and continue to build upon the legacy Vladimiro and his family have developed over the past three decades.”
Headquartered in Martinengo, near Bergamo, Italy, Diapath was founded in 1997 by Vladimiro Bergamini. Over the past 27 years, focused investments have enabled the business to expand beyond consumables manufacturing and into the design, development, and production of a variety of core histology instruments.
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. The Diapath Donatello automatic tissue processor won a prestigious A’Design Award for Scientific Instruments, and the T-Filler Automatic Formalin dispenser protects technicians from chemical exposure while ensuring specimens receive the correct ratio of formalin. In addition to their strong Italian presence, Diapath’s subsidiaries support focused growth of Diapath products to laboratories in Germany and France.
“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs,” said Vladimiro Bergamini, CEO & President of Diapath. “Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing. I’m looking forward to the work my team will do with Dae and StatLab to leverage our combined global manufacturing capabilities to capture new business opportunities.”
About StatLab Medical Products
StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and labeling and tracking equipment from eight manufacturing sites in the United States, United Kingdom, and Germany. Our global operational footprint powered by over 600 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. Learn more at StatLab.com.
About Diapath
Diapath is a leading Italian company specializing in the design, development, and manufacturing of advanced histology and cytology instruments and consumables. With nearly three decades of experience, Diapath is committed to innovation and excellence, offering cutting-edge solutions that redefine laboratory processes to ensure increasingly reliable diagnostics for better cancer care. Our products, distinguished by their Italian design and quality, range from processors and stainers to embedding centers and more, supporting the entire anatomic pathology workflow. Dedicated to enhancing histological research and diagnostics, Diapath continues to set industry standards with a focus on quality and innovation. Learn more at Diapath.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828096902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom